Get the Stockscreener App
3.38
6.37%
-0.23
After Hours:
3.38
Maxcyte Inc stock is traded at $3.38, with a volume of 952.38K.
It is down -6.37% in the last 24 hours and down -5.32% over the past month.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
See More
Previous Close:
$3.61
Open:
$3.6
24h Volume:
952.38K
Relative Volume:
2.10
Market Cap:
$380.79M
Revenue:
$45.44M
Net Income/Loss:
$-35.43M
P/E Ratio:
-10.56
EPS:
-0.32
Net Cash Flow:
$-25.39M
1W Performance:
+1.50%
1M Performance:
-5.32%
6M Performance:
-25.55%
1Y Performance:
-27.78%
1-Day Range:
$3.33
$3.61
1-Week Range:
$3.295
$3.75
52-Week Range:
$3.165
$5.545
Maxcyte Inc Stock (MXCT) Company Profile
Name
Maxcyte Inc
Sector
Industry
Phone
301-517-5556
Address
9713 KEY WEST AVENUE,, ROCKVILLE
Compare MXCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
3.38 | 380.79M | 45.44M | -35.43M | -25.39M | -0.32 |
|
ABT
Abbott Laboratories
|
117.96 | 203.52B | 41.22B | 5.77B | 6.49B | 2.94 |
|
SYK
Stryker Corp
|
389.71 | 148.24B | 21.97B | 3.59B | 3.21B | 6.74 |
|
BSX
Boston Scientific Corp
|
90.21 | 132.25B | 15.91B | 1.79B | 1.89B | 0.82 |
|
MDT
Medtronic Plc
|
85.68 | 109.12B | 33.00B | 4.29B | 5.50B | 2.71 |
|
EW
Edwards Lifesciences Corp
|
71.55 | 42.07B | 6.60B | 4.16B | 490.10M | 2.34 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-23 | Initiated | Craig Hallum | Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-24-21 | Initiated | BTIG Research | Buy |
| Aug-24-21 | Initiated | Cowen | Outperform |
| Aug-24-21 | Initiated | Stephens | Overweight |
| Aug-24-21 | Initiated | Stifel | Buy |
| Aug-24-21 | Initiated | Wedbush | Outperform |
| Aug-24-21 | Initiated | William Blair | Outperform |
View All
Maxcyte Inc Stock (MXCT) Latest News
Electroporation Enables Efficient Antibody Discovery By Mammalian Display - BioProcess Online
This MaxCyte Insider Increased Their Holding In The Last Year - Yahoo Finance
MaxCyte celebrates 25 years of innovation driving cell engineering-based therapeutics - MSN
MaxCyte stock touches 52-week low at $3.23 amid market challenges - Investing.com
Will MaxCyte's Q2 Results Surpass Market Expectations? - RTTNews
CADIAN CAPITAL MANAGEMENT, LP Expands Stake in MaxCyte Inc - GuruFocus.com
MaxCyte Celebrates 25 Years - Baystreet.ca
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics - The Manila Times
MaxCyte Marks 25 Years of Innovation with Groundbreaking Cell Therapy Breakthrough | MXCT Stock News - StockTitan
MaxCyte stock touches 52-week low at $3.27 amid market shifts - Investing.com Canada
MaxCyte stock touches 52-week low at $3.27 amid market shifts By Investing.com - Investing.com South Africa
500: Something went wrong - Investing.com
FY2024 Earnings Estimate for MaxCyte Issued By William Blair - MarketBeat
MaxCyte, Inc. (NASDAQ:MXCT) Q3 2024 Earnings Call Transcript - MSN
MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates - MSN
Investors ignore increasing losses at MaxCyte (LON:MXCT) as stock jumps 10% this past week - Simply Wall St
MaxCyte Files Quarterly Report, Highlights Financial Progress - TipRanks
MaxCyte’s Revenue Grows and Strategic Moves Unveiled - TipRanks
MaxCyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Constellation Energy Corp (CEG-Q) QuotePress Release - The Globe and Mail
MaxCyte Director Sells Shares Amid Active Trading - TipRanks
MaxCyte Expands Stock Capital with New Issuance - TipRanks
MaxCyte (LON:MXCT) Stock Passes Below 50 Day Moving AverageTime to Sell? - MarketBeat
MaxCyte to Participate in Two Upcoming Investor Conferences - StockTitan
MaxCyte to Join Key Investor Conferences in November - TipRanks
MaxCyte’s Insider Stock Activity in Focus - TipRanks
MaxCyte director Johnston sells $11,166 in stock - Investing.com
Overcome the limitations of conventional transfection with MaxCyte Electroporation - LabRoots
MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 65% of the company - Yahoo Finance
MaxCyte (MXCT) to Release Quarterly Earnings on Wednesday - MarketBeat
Grant of Options and Restricted Stock Units - ShareCast
MaxCyte Awards Stock Options to Boost Growth - TipRanks
MaxCyte (MXCT) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
MaxCyte Appoints Cynthia Collins to its Board of Directors - ForexTV.com
MaxCyte Strengthens Board with Cynthia Collins Appointment - TipRanks
MaxCyte appoints Ali Soleymannezhad as Chief Commercial Officer - Head Topics
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024 - ForexTV.com
MaxCyte to Unveil Q3 2024 Financial Results - TipRanks
People on the Move: Ali Soleymannezhad, Chief Commercial Officer, MaxCyte - BioBuzz
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer - citybiz
MaxCyte appoints new chief commercial officer - ShareCast
MaxCyte appoints Soleymannezhad as CCO - TipRanks
MaxCyte Names New CCO for Market Expansion - TipRanks
MaxCyte upgraded to Buy from Hold at Deutsche Bank - TipRanks
Marshall Wace LLP Acquires New Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - MarketBeat
Maxcyte: Reaching Financial Inflection With CASGEVY Ramp Up (NASDAQ:MXCT) - Seeking Alpha
Stan Erck Sells 47,689 Shares of MaxCyte, Inc. (LON:MXCT) Stock - MarketBeat
MaxCyte, Inc. (LON:MXCT) Insider Sells £185,033.32 in Stock - Defense World
Maxcyte Inc Stock (MXCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.03%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):